Artivion (NYSE:AORT – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.
Profitability
This table compares Artivion and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artivion | -4.43% | 5.70% | 2.29% |
| Delcath Systems | 3.18% | 6.91% | 5.80% |
Valuation & Earnings
This table compares Artivion and Delcath Systems”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artivion | $422.65 million | 5.12 | -$13.36 million | ($0.24) | -190.48 |
| Delcath Systems | $79.60 million | 3.96 | -$26.39 million | $0.01 | 893.00 |
Artivion has higher revenue and earnings than Delcath Systems. Artivion is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Artivion and Delcath Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artivion | 1 | 1 | 7 | 0 | 2.67 |
| Delcath Systems | 1 | 0 | 5 | 0 | 2.67 |
Artivion presently has a consensus target price of $49.11, indicating a potential upside of 7.44%. Delcath Systems has a consensus target price of $22.40, indicating a potential upside of 150.84%. Given Delcath Systems’ higher probable upside, analysts clearly believe Delcath Systems is more favorable than Artivion.
Insider & Institutional Ownership
86.4% of Artivion shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 7.6% of Artivion shares are owned by insiders. Comparatively, 17.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Artivion has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Summary
Delcath Systems beats Artivion on 7 of the 13 factors compared between the two stocks.
About Artivion
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
